Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$213K Sell
7,582
-3,575
-32% -$95.2K 0.03% 129
2025
Q4
$278K Sell
11,157
-2,720
-20% -$68.6K 0.04% 122
2025
Q3
$354K Sell
13,877
-2,300
-14% -$56.8K 0.05% 118
2025
Q2
$392K Sell
16,177
-4,865
-23% -$113K 0.06% 113
2025
Q1
$533K Sell
21,042
-1,443
-6% -$37.8K 0.09% 109
2024
Q4
$597K Buy
22,485
+700
+3% +$19K 0.09% 105
2024
Q3
$630K Sell
21,785
-410
-2% -$12K 0.1% 103
2024
Q2
$621K Buy
22,195
+360
+2% +$9.91K 0.11% 99
2024
Q1
$606K Buy
21,835
+4,275
+24% +$119K 0.1% 102
2023
Q4
$506K Buy
17,560
+5,705
+48% +$172K 0.09% 103
2023
Q3
$393K Buy
11,855
+1,135
+11% +$40.1K 0.08% 106
2023
Q2
$393K Buy
10,720
+1,600
+18% +$62.3K 0.08% 104
2023
Q1
$372K Buy
9,120
+1,200
+15% +$51.8K 0.08% 105
2022
Q4
$406K Hold
7,920
0.09% 102
2022
Q3
$346K Buy
7,920
+650
+9% +$31.6K 0.08% 104
2022
Q2
$381K Hold
7,270
0.08% 104
2022
Q1
$376K Hold
7,270
0.07% 105
2021
Q4
$429K Hold
7,270
0.08% 104
2021
Q3
$312K Buy
+7,270
New +$322K 0.06% 104

Other funds holding PFE

Culbertson A N & Co's PFE Position: Q1 2026 in Review

Culbertson A N & Co reduced its Pfizer (PFE) stake by 32% in Q1 2026, selling an estimated $95.2K and leaving 7,582 shares worth $213K. The position accounts for 0.03% of the portfolio, ranked #129.

Culbertson A N & Co first reported a position in PFE in Q3 2021 and has held it in 19 quarters since. The position peaked at $630K in Q3 2024. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Culbertson A N & Co held 7,582 shares of Pfizer worth $213K as of Q1 2026.
  • Culbertson A N & Co sold 3,575 Pfizer shares in Q1 2026, an estimated $95.2K.
  • Pfizer made up 0.03% of Culbertson A N & Co's portfolio in Q1 2026, its #129 holding.
  • Culbertson A N & Co first reported a position in Pfizer in Q3 2021 and has held it in 19 quarters since.
  • Culbertson A N & Co's Pfizer position peaked at $630K in Q3 2024.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Culbertson A N & Co's 13F filing for Q1 2026, filed 12 May 2026.